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 Multidrug-resistant tuberculosis (MDR-TB) 
and extensively drug-resistant tuberculosis (XDR-
TB) have emerged as significant threats to global 
tuberculosis (TB) control. The magnitude of the 
problem is evident from the fourth global report of the 
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Background & objective: Extensively drug-resistant tuberculosis (XDR-TB) is a difficult-to-treat form of 
multidrug-resistant tuberculosis (MDR-TB). High rates of XDR-TB have been reported from India. We 
sought to ascertain the prevalence of XDR-TB among patients with MDR-TB treated at a tertiary care 
centre in New Delhi, India.
Methods: Case records of patients treated for MDR-TB at the All India Institute of Medical Sciences 
hospital, New Delhi, between 1997 and 2003 were retrospectively reviewed. All patients underwent a pre-
treatment drug-susceptibility testing (DST) to first- as well as second-line drugs. XDR-TB was defined as 
TB caused by bacilli showing resistance to rifampicin and isoniazid in addition to any fluoroquinolone 
and to at least one of the three following injectable drugs: capreomycin, kanamycin, and amikacin.
Results: A total of 211 laboratory-confirmed cases of MDR-TB were reviewed. The mean age of the 
patients was 33 ± 12 yr. Fifty one (24%) patients were females. All patients were sero-negative for human 
immunodeficiency virus infection. Five of the 211 MDR-TB patients had XDR-TB. The prevalence of 
XDR-TB was 2.4 per cent among MDR-TB patients.
Interpretation & conclusion: Our results showed that XDR-TB was rare among patients with MDR-TB 
treated between 1997 and 2003 at our centre. Unreported selection bias might have been responsible for 
the high prevalence of XDR-TB reported in previous hospital-based studies from India. 
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World Health Organization (WHO) which reported 
data from 81 countries across the globe1. Currently, 
MDR-TB accounts for 5.3 per cent of all TB cases 
in the world, with the prevalence among new and 
previously treated cases being 2.9 and 15.3 per cent 
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respectively. This report also has data on XDR-TB in 
which second-line drug susceptibility testing (DST) 
was carried out on 4012 MDR-TB isolates from 35 
countries; among these, 301 (7%) were found to 
be extensively drug-resistant1. As of June 2008, 49 
countries have reported laboratory confirmed XDR-
TB cases to the WHO2. The exact prevalence of 
XDR-TB in most regions of the world is currently 
unknown. A few earlier hospital-based studies from 
India have reported alarmingly high rates of XDR-
TB among patients with MDR-TB3-5. However, our 
personal experience in treating a large number of 
patients with MDR-TB is that XDR-TB would be 
uncommon in our setting. In order to confirm this 
anecdotal observation, we formally set out to ascertain 
the prevalence of XDR-TB among patients treated for 
MDR-TB at a tertiary care centre in New Delhi. 
Material & Methods
 The case records of patients with MDR-TB treated, 
during the period from 1997 through 2003, at the 
All India Institute of Medical Sciences (AIIMS) hospital, 
New Delhi were retrospectively reviewed. AIIMS is a 
large, tertiary level teaching hospital located in northern 
India. Before the initiation of treatment for MDR-TB, 
all patients underwent mycobacterial culture and DST 
at the New Delhi Tuberculosis Centre Laboratory, 
New Delhi. This laboratory was a supranational 
reference laboratory of the WHO during the study 
period. Cultures were done on Lowenstein-Jensen 
(LJ) slopes by Petroff’s method6. Niacin test, catalase 
test and para-nitrobenzoic acid (PNB) test were 
used to identify the isolated mycobacteria. DST was 
carried out by the proportion method for first-
line drugs and resistance ratio method for 
second-line drugs7. The tested drugs and 
their critical concentrations (in µg/ml) were as 
follows: isoniazid - 0.2, rifampicin - 40, pyrazinamide 
- 100, ethambutol - 2, streptomycin - 4, kanamycin 
- 64, ciprofloxacin - 8, ofloxacin - 8, ethionamide 
- 320, cycloserine - 160, para-aminosalicylic acid - 4, 
thiacetazone - 4, and clarithromycin - 128. MDR-TB 
was defined as TB caused by bacilli showing resistance 
to at least isoniazid and rifampicin. XDR-TB was 
defined as TB caused by bacilli resistant to rifampicin 
and isoniazid in addition to any fluoroquinolone and 
at least one of the three injectable second-line drugs: 
capreomycin, kanamycin and amikacin8. Human 
immunodeficiency virus (HIV) testing was carried out 
routinely in all patients.
Results
 Of the 211 patients with MDR-TB, 67.4 per cent 
came from various States outside Delhi and 32.6 per cent 
from within Delhi. Most (98%, n = 207) of these patients 
had a history of previous treatment for tuberculosis. 
Only four patients were naïve to anti-tuberculous 
drugs. The mean age of the patients was 33 ± 12 yr; 51 
(24%) patients were female. The mean body mass index 
was 17.3 ± 3.0 kg/m2. All patients tested negative for 
HIV infection. The resistance rates to various first and 
second-line drugs observed are shown in Table I. Of 
the 211 patients, 21 patients (10%) showed resistance 
to one of the fluoroquinolones and 14 (6.6%) showed 
resistance to the injectable agent, kanamycin. Five 
cases of XDR-TB were detected. Thus, the prevalence 
of XDR-TB among MDR-TB patients was 2.4 per 
cent. Among the five XDR-TB patients, two patients 
had a definite history of previous treatment with 
second-line drugs; the remaining three patients had 
multiple previous courses of anti-tuberculosis therapy 
which most likely included second-line agents, but no 
detailed records were available. Table II shows the 
characteristics of the patients with XDR-TB. 
Discussion
 We found that XDR-TB was rare among patients 
treated for MDR-TB at our centre. Our findings do not 
support the earlier reports of frequent occurrence of 
XDR-TB in India. The reported prevalence of XDR-
TB in these hospital-based studies varied from 7.4 - 
33.3 per cent (Table III). However, a population-based 
study from southern India suggested a low prevalence 
of XDR-TB9; notably, DST was performed at a WHO-
accredited laboratory in this study. Our findings are 
 Table I. Resistance rates to various first-line and second-line drugs 
among MDR-TB patients*
First-line drug Resistance 
rate (%)
Second-line  
drug
Resistance  
rate (%)
Isoniazid 
Rifampicin
Pyrazinamide
Ethambutol
Streptomycin 
100
100
8.1
20.9
49.8
Kanamycin
Ciprofloxacin 
Ofloxacin 
Sparfloxacin 
Cycloserine 
Ethionamide 
Clofazimine 
PAS
Thiacetazone 
6.6
9.5
9.0
4.8
4.3
3.8
1.9
2.4
8.7
*Note - 206 patients were tested for thiacetazone, 209 patients for 
cycloserine, 209 patients for clofazimine, and 208 patients for 
sparfloxacin. Other drugs were tested in all 211 patients.
PAS, para-aminosalicylic acid
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in consonance with such an observation. The high 
rates of XDR-TB observed in previous hospital-based 
studies might be due to referral bias. Moreover, the 
DST was not performed at quality-assured, accredited 
laboratories in any of these studies. HIV infection and 
local failure of the control programme could have also 
possibly contributed to varying rates of drug-resistant 
TB in these studies and so is the small number of 
patients included in some studies.
 The discrepancy in findings between the present 
and an earlier study5 from the same institution can 
be explained by the difference in the nature of the 
two studies. The previous study5 was conducted in 
full-blown AIDS patients and therefore, the basic 
study population was different from the present study. 
Although the present study was also hospital-based, 
we found that XDR-TB was rare. Notwithstanding, in 
our study, the DST was performed at a supranational 
reference laboratory. Perhaps, this might be one of the 
reasons for the discordant observations.
 Another interesting observation was that none of 
the patients with MDR-TB was HIV co-infected in the 
present study. This finding is in agreement with previous 
studies on drug-resistant TB that had shown that HIV 
infection is not more common among drug-resistant TB 
patients than in the general population10-12, although there 
are studies which contradict this finding13,14. Though 
there are extensive data on HIV prevalence in TB as a 
whole, there have been only a few studies on prevalence 
of HIV among MDR-TB patients from India. In a study 
conducted in Chennai, HIV seropositivity among MDR-
TB patients was 4.42 per cent15, which is comparable 
to rates of HIV observed among ordinary TB patients. 
It is possible that HIV co-infected patients with MDR-
TB succumbed to the illness before they could be 
diagnosed. 
 There are certain limitations to the present study. 
First, due to its retrospective nature, the study may 
not truly reflect the current pattern of drug resistance. 
It is well known that drug resistance is a dynamic 
phenomenon that needs to be studied in real-time. 
Second, being a hospital-based study, the present 
observations cannot be extrapolated to the community 
settings. Nonetheless, the low prevalence of XDR-TB 
in this referral population is reassuring.
 The present observation, however, should not lead 
to a state of complacency. Large-scale representative 
population-based data are urgently needed to find out 
the true prevalence of XDR-TB in the community. 
Periodic drug-resistance surveillance should become 
a part of the national TB control programmes. It is 
important to improve the laboratory infrastructure 
and establish a nationwide network of quality-assured 
laboratories capable of carrying out second-line 
Table II. Characteristics of the patients with XDR-TB
S.No. Age/Sex Body-mass index
(kg/m2)
Previous  
treatment for TB
Previous use of 
second-line drugs
Type of TB Pattern of drug resistance
1
66
100
142
180
42 / Male
40 / Male
58 / Male
25 / Male
24 / Male
15.2
15.4
17.2
16
18
Yes
Yes
Yes
Yes
Yes
N.A
N.A
N.A
Yes
Yes
Pulmonary
Pulmonary 
Pulmonary
Pulmonary 
Pulmonary  
R, H, K, Of, Cip, Thi
R, H, S, K, Cip
R, H, E, S, K, Cip, Of, Spar, Thi, 
Clof, Cyc, Et, PAS
R, H, K, Cip, Of
R, H, S, K, Cip, Of 
Cip, ciprofloxacin; Clof, clofazimine; Cyc, cycloserine; E, ethambutol; Et, ethionamide; H, isoniazid; K, kanamycin; Of, ofloxacin; PAS, 
para-aminosalicylic acid; R, rifampicin; S, streptomycin; Spar, sparfloxacin; Thi, thiacetazone; N.A, Not available
Table III. Published studies on the prevalence of XDR-TB in India
Study Setting No. of MDR-TB  
patients
No. of HIV-infected patients Prevalence of XDR-TB, 
 n (%)
Mondal et al3
Jain et al4
Singh et al5
Thomas et al9
Present study
Tertiary care centre, Lucknow
Tertiary care centre, Mumbai
Tertiary care centre, New Delhi
Field trial, Chennai
Tertiary care centre, New Delhi
68 
326 
12
66
211
Not reported
Not reported 
All HIV-infected
Not reported
All HIV-negative
5 (7.4)
36 (11)
4 (33.3)
1 (1.5)
5 (2.4)
MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis
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DST. Second-line drugs must be used judiciously 
and cautiously by physicians at all levels of medical 
care. Irrational use of second-line drugs, like adding 
fluoroquinolones to a first-line regimen or a failing 
regimen, should be avoided. Future large-scale 
population-based prospective studies should throw 
light on the prevalence of XDR-TB in the community.
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